Is KALV or KPRX more undervalued in 2026?

CirclFi compares KalVista Pharmaceuticals, Inc. (KALV) and Kiora Pharmaceuticals, Inc. (KPRX) using 13 institutional-grade valuation models. KALV has a Quality of Company score of 6.3/10 while KPRX scores 5.5/10.

Which is a better buy — KALV or KPRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KALV and KPRX valuations compare?

KALV at $26.77 and KPRX at $2.83 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KALV vs KPRX Valuation Comparison 2026 — Intrinsic Value Analysis

KALV

Biotechnology

KalVista Pharmaceuticals, Inc.

Quality

6.3

out of 10

Value Trap

LOW

Price

$26.77

Last close

Models

8/13

Active

KPRX

Biotechnology

Kiora Pharmaceuticals, Inc.

Quality

5.5

out of 10

Value Trap

LOW

Price

$2.83

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	KALV Fair Value	KALV Upside	KPRX Fair Value	KPRX Upside
Bayesian DCF	Intrinsic	$8.49	-68.3%	$2.06	-27.1%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	—	—	$0.48	-80.2%
Dynamic NAV	Asset-Based	$5.03	-81.2%	$4.83	+70.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KALV vs KPRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KALV vs KPRX — Which Stock Is More Undervalued?

KALV scores higher with a 6.3/10 quality rating vs KPRX's 5.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing KalVista Pharmaceuticals, Inc. (KALV) and Kiora Pharmaceuticals, Inc. (KPRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KALV currently trades at $26.77 with a QOC of 6.3/10, while KPRX trades at $2.83 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).